Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Yusuke Shimodaira, Elena Elimova, Roopma Wadhwa, Hironori Shiozaki, Nikolaos Charalampakis, Venkatram Planjery, Mariela A Blum, Jeannelyn S Esteralla, Jane E Rogers, Shumei Song & Jaffer A Ajani. (2015) Ramucirumab for the treatment of gastroesophageal cancers. Expert Opinion on Orphan Drugs 3:6, pages 737-746.
Read now
Read now
Olav Dahl. (2009) Follow up your unexpected clinical observations!. Acta Oncologica 48:3, pages 325-327.
Read now
Read now
Yixing Jiang, Eric T Kimchi, Alberto J Montero, Kevin F Staveley-O’Carroll & Jaffer A Ajani. (2008) Upper gastrointestinal tumors: current status and future perspectives. Expert Review of Anticancer Therapy 8:6, pages 975-991.
Read now
Read now
Articles from other publishers (19)
Min Shi, Zhongyin Yang, Sheng Lu, Wentao Liu, Zhentian Ni, Xuexin Yao, Zichen Hua, Runhua Feng, Yanan Zheng, Zhenqiang Wang, Birendra Kumar Sah, Mingmin Chen, Zhenglun Zhu, Changyu He, Chen Li, Jun Zhang, Chao Yan, Min Yan & Zhenggang Zhu. (2021) Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases. BMC Cancer 21:1.
Crossref
Crossref
Shin Saito, Hironori Yamaguchi, Hideyuki Ohzawa, Hideyo Miyato, Rihito Kanamaru, Kentaro Kurashina, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata & Joji Kitayama. (2020) Intraperitoneal Administration of Paclitaxel Combined with S-1 Plus Oxaliplatin as Induction Therapy for Patients with Advanced Gastric Cancer with Peritoneal Metastases. Annals of Surgical Oncology 28:7, pages 3863-3870.
Crossref
Crossref
Hideyuki Ohzawa, Yuki Kimura, Akira Saito, Hironori Yamaguchi, Hideyo Miyato, Yasunaru Sakuma, Hisanaga Horie, Yoshinori Hosoya, Alan Kawarai Lefor, Naohiro Sata & Joji Kitayama. (2020) Ratios of miRNAs in Peritoneal Exosomes are Useful Biomarkers to Predict Tumor Response to Intraperitoneal Chemotherapy in Patients with Peritoneal Metastases from Gastric Cancer. Annals of Surgical Oncology 27:13, pages 5057-5064.
Crossref
Crossref
David Malka, Eric François, Frédérique Penault-Llorca, Florence Castan, Olivier Bouché, Jaafar Bennouna, François Ghiringhelli, Christelle de la Fouchardière, Christophe Borg, Emmanuelle Samalin, Jean-Baptiste Bachet, Jean-Luc Raoul, Laurent Miglianico, Leila Bengrine-Lefèvre, Laetitia Dahan, Cédric Lecaille, Thomas Aparicio, Trevor Stanbury, Hervé Perrier, Anne Cayre, Pierre Laurent-Puig, Sophie Gourgou, Jean-François Emile & Julien Taïeb. (2019) FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial. European Journal of Cancer 115, pages 97-106.
Crossref
Crossref
Sung Yong Oh, Aesun Shin, Seong-Geun Kim, Jung-Ah Hwang, Seung Hyun Hong, Yeon-Su Lee & Hyuk-Chan Kwon. (2016) Relationship between insulin-like growth factor axis gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX. Oncotarget 7:21, pages 31204-31214.
Crossref
Crossref
Lamiss Mohamed Abd el Aziz. (2014) Blood neutrophil–lymphocyte ratio predicts survival in locally advanced cancer stomach treated with neoadjuvant chemotherapy FOLFOX 4. Medical Oncology 31:12.
Crossref
Crossref
Laura W. Goff, Nilay Thakkar, Liping Du, Emily Chan, Benjamin R. Tan, Dana B. Cardin, Howard L. McLeod, Jordan D. Berlin, Barbara Zehnbauer, Chloe Fournier, Joel Picus, Andrea Wang-Gillam, Wooin Lee & A. Craig Lockhart. (2014) Thymidylate Synthase Genotype-Directed Chemotherapy for Patients with Gastric and Gastroesophageal Junction Cancers. PLoS ONE 9:9, pages e107424.
Crossref
Crossref
Zheng-mao Lu, Tian-hang Luo, Ming-ming Nie, Guo-en Fang, Li-ye Ma, Xu-chao Xue, Guo Wei, Chong-we Ke & Jian-wei Bi. (2013) Influence of ERCC1 and ERCC4 polymorphisms on response to prognosis in gastric cancer treated with FOLFOX-based chemotherapy. Tumor Biology 35:4, pages 2941-2948.
Crossref
Crossref
Sung Yong Oh, Hyuk-Chan Kwon, Sung Hyun Kim, Suee Lee, Ji Hyun Lee, Jung-Ah Hwang, Seung Hyun Hong, Christian A Graves, Kevin Camphausen, Hyo-Jin Kim & Yeon-Su Lee. (2013) The relationship of Vascular endothelial growth factor gene polymorphisms and clinical outcome in advanced gastric cancer patients treated with FOLFOX: VEGF polymorphism in gastric cancer. BMC Cancer 13:1.
Crossref
Crossref
Suee Lee, Sung Yong Oh, Sung Hyun Kim, Ji Hyun Lee, Min Chan Kim, Ki Han Kim & Hyo-Jin Kim. (2013) Prognostic significance of neutrophil lymphocyte ratio and platelet lymphocyte ratio in advanced gastric cancer patients treated with FOLFOX chemotherapy. BMC Cancer 13:1.
Crossref
Crossref
Ryutaro Mori, Kazuhiro Yoshida, Toshiyuki Tanahashi, Kazunori Yawata, Junko Kato, Naoki Okumura, Yasuhiro Tsutani, Morihito Okada, Naohide Oue & Wataru Yasui. (2012) Decreased FANCJ caused by 5FU contributes to the increased sensitivity to oxaliplatin in gastric cancer cells. Gastric Cancer 16:3, pages 345-354.
Crossref
Crossref
Ji Hyun LeeSung-Hyun KimSung Yong OhSuee LeeHojin LeeHye Jung LeeHyo-Jin Kim. (2013) Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer. The Korean Journal of Internal Medicine 28:3, pages 314.
Crossref
Crossref
Sung Rok Kim, Young Jin Yuh, Byeong Seok Sohn & Sung Hyun Yang. (2018) A Phase II Trial of 5-Fluorouracil, Leucovorin and Mitomycin C in Patients with Advanced Gastric Cancer. Tumori Journal 97:6, pages 698-703.
Crossref
Crossref
Yixing Jiang & Jaffer A Ajani. (2010) Multidisciplinary management of gastric cancer. Current Opinion in Gastroenterology 26:6, pages 640-646.
Crossref
Crossref
Hee Yeon Seo, Dae Sik Kim, Yoon Seok Choi, Hwa Jung Sung, Kyong Hwa Park, In Keun Choi, Seok Jin Kim, Sang Cheul Oh, Jae Hong Seo, Chul Won Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim & Jun Suk Kim. (2008) Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Cancer Chemotherapy and Pharmacology 63:3, pages 433-439.
Crossref
Crossref
Tomislav Dragovich & Christopher Campen. (2009) Anti-EGFR-Targeted Therapy for Esophageal and Gastric Cancers: An Evolving Concept. Journal of Oncology 2009, pages 1-8.
Crossref
Crossref
Yoon-Koo Kang. (2009) Phase I/II studies of combination chemotherapy with S-1 and platinum in patients with previously untreated metastatic or recurrent gastric cancer. Gastric Cancer 12:S1, pages 38-42.
Crossref
Crossref
Qilian Liang, Saihong Chen, Dachao Pan, Jierong Xie, Liangzhen Cai & Shujun Li. (2008) Treatment of advanced gastric carcinoma patients with calcium folinate, a 5-fluorouracil bolus and continous infusion with 5-fluorouracil combined with oxaliplatin. Chinese Journal of Clinical Oncology 5:4, pages 273-276.
Crossref
Crossref
Wei-Shou Hwang, Tsu-Yi Chao, Shen-Fung Lin, Chih-Yuan Chung, Chang-Fang Chiu, Yi-Fang Chang, Po-Min Chen & Tzeon-Jye Chiou. (2008) Phase II study of oxaliplatin in combination with continuous infusion of 5-fluorouracil/leucovorin as first-line chemotherapy in patients with advanced gastric cancer. Anti-Cancer Drugs 19:3, pages 283-288.
Crossref
Crossref